CLOs on the Move

The Davidson Transfer

www.davidsontransfer.com

 
The Davidson Transfer is a Baltimore, MD-based company in the Business Services sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Gresyton Bakery

Gresyton Bakery is a Yonkers, NY-based company in the Business Services sector.

Doring Inc

Doring Inc is a Troy, MI-based company in the Business Services sector.

Kynetec

Kynetec is a global leader in market research focused on the animal health and agriculture sectors. Established in the UK, the company has evolved through significant transformations, including mergers and acquisitions. In 2015, Kynetec was relaunched following a management buyout, supported by private equity investment. The company offers customized research methodologies, market tracking, and forecasting studies. These services assist clients in developing strategic business plans, launching new products, and refining marketing strategies. Kynetecs expertise covers various areas, including animal health, farm animal nutrition, crop protection, farm machinery, and seeds/biotech. One of its key products, PetTrak, provides monthly sales insights for the veterinary channel. With operations in over 80 countries and a team of more than 500 professionals, Kynetec serves a diverse range of clients in the agribusiness and animal health industries. The company is backed by significant investments from private equity firms, which have supported its growth and expansion.

O Henrys Coffee

O Henrys Coffee is a Birmingham, AL-based company in the Business Services sector.

Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical­-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopars pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR­101, a late-­stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR­202, an early-stage camsirubicin analog for various cancers.